循环胆汁酸在人类内毒素血症和脓毒性休克中的免疫抑制作用:肝衰竭患者处于风险之中
该研究通过10名健康志愿者接受2 ng/kg大肠杆菌脂多糖(LPS)诱导实验性内毒素血症,并分析48例早期(休克发作<24 h)严重脓毒性休克患者(去甲肾上腺素剂量>0.4 μg/kg/min)及48名年龄性别匹配健康对照的循环胆汁酸谱。结果显示,实验性内毒素血症和脓毒性休克总体胆汁酸仅轻度升高,但合并严重肝衰竭的脓毒性休克患者胆汁酸显著升高(61.8 µmol/L vs 2.8 µmol/L,p=0.0016),且其胆汁酸诱导TGR5激活显著增加(20.4% vs 2.8%,p=0.0139),提示免疫抑制。作者认为未来应研究调节胆汁酸代谢能否改善这类患者的临床病程与结局。
要点
- 脓毒性休克合并严重肝衰竭患者循环胆汁酸显著升高:61.8 µmol/L vs 健康对照 2.8 µmol/L,p=0.0016。
- 该类患者循环胆汁酸诱导TGR5激活显著增加:20.4% vs 健康对照 2.8%,p=0.0139,提示免疫抑制。
- 实验性内毒素血症(10名健康志愿者,2 ng/kg大肠杆菌LPS)及脓毒性休克总体胆汁酸较对照显著升高,但多数病例升高轻微。
- 研究纳入48例早期(休克发作<24 h)严重脓毒性休克患者(去甲肾上腺素剂量>0.4 μg/kg/min)及48名年龄性别匹配健康对照。
- 作者认为未来应研究调节胆汁酸代谢能否改善合并严重肝衰竭的脓毒症患者的临床病程和结局。
适用人群与场景
- 10名健康志愿者接受2 ng/kg大肠杆菌脂多糖(LPS)诱导实验性内毒素血症。
- 48例早期(休克发作<24 h)严重脓毒性休克患者(去甲肾上腺素剂量>0.4 μg/kg/min)。
- 48名年龄和性别匹配的健康对照。
研究设计与关键结果
- 研究类型:人类实验性内毒素血症研究及脓毒性休克患者对照分析。
- 实验性内毒素血症(10名健康志愿者,2 ng/kg大肠杆菌LPS)及脓毒性休克患者总体循环胆汁酸较对照显著升高,但多数病例升高轻微。
- 合并严重肝衰竭的脓毒性休克患者循环胆汁酸显著升高:61.8 µmol/L vs 健康对照 2.8 µmol/L,p=0.0016。
- 合并严重肝衰竭的脓毒性休克患者循环胆汁酸诱导TGR5激活显著增加:20.4% vs 健康对照 2.8%,p=0.0139。
- 采用近期发表的公式计算每个个体胆汁酸谱诱导TGR5激活的能力,以筛查循环胆汁酸的免疫抑制效应。
证据类型、等级与局限
- 证据类型:人类实验性内毒素血症研究及病例对照分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来应研究调节胆汁酸代谢能否改善合并严重肝衰竭的脓毒症患者的临床病程和结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-induced immunosuppression is a frequent cause of opportunistic infections and death in critically ill patients. A better understanding of the underlying mechanisms is needed to develop targeted therapies. Circulating bile acids with immunosuppressive effects were recently identified in critically ill patients. These bile acids activate the monocyte G-protein coupled receptor TGR5, thereby inducing profound innate immune dysfunction. Whether these mechanisms contribute to immunosuppression and disease severity in sepsis is unknown. The aim of this study was to determine if immunosuppressive bile acids are present in endotoxemia and septic shock and, if so, which patients are particularly at risk.
METHODS: To induce experimental endotoxemia in humans, ten healthy volunteers received 2 ng/kg E. coli lipopolysaccharide (LPS). Circulating bile acids were profiled before and after LPS administration. Furthermore, 48 patients with early (shock onset within < 24 h) and severe septic shock (norepinephrine dose > 0.4 μg/kg/min) and 48 healthy age- and sex-matched controls were analyzed for circulating bile acids. To screen for immunosuppressive effects of circulating bile acids, the capability to induce TGR5 activation was computed for each individual bile acid profile by a recently published formula.
RESULTS: Although experimental endotoxemia as well as septic shock led to significant increases in total bile acids compared to controls, this increase was mild in most cases. By contrast, there was a marked and significant increase in circulating bile acids in septic shock patients with severe liver failure compared to healthy controls (61.8 µmol/L vs. 2.8 µmol/L, p = 0.0016). Circulating bile acids in these patients were capable to induce immunosuppression, as indicated by a significant increase in TGR5 activation by circulating bile acids (20.4% in severe liver failure vs. 2.8% in healthy controls, p = 0.0139).
CONCLUSIONS: Circulating bile acids capable of inducing immunosuppression are present in septic shock patients with severe liver failure. Future studies should examine whether modulation of bile acid metabolism can improve the clinical course and outcome of sepsis in these patients.
参考来源
- Leonhardt J, Dorresteijn MJ, Neugebauer S, et al. Immunosuppressive effects of circulating bile acids in human endotoxemia and septic shock: patients with liver failure are at risk. Crit Care. 2023. PMID: 37759239. doi:10.1186/s13054-023-04620-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。